1. Home
  2. HBT vs LBRX Comparison

HBT vs LBRX Comparison

Compare HBT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HBT Financial Inc.

HBT

HBT Financial Inc.

N/A

Current Price

$35.68

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$48.80

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HBT
LBRX
Founded
1920
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
HBT
LBRX
Price
$35.68
$48.80
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$30.75
$46.60
AVG Volume (30 Days)
129.7K
363.8K
Earning Date
04-27-2026
05-06-2026
Dividend Yield
3.29%
N/A
EPS Growth
7.96
98.22
EPS
1.12
N/A
Revenue
N/A
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
$7.01
N/A
P/E Ratio
$32.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.36
$13.40
52 Week High
$37.51
$49.97

Technical Indicators

Market Signals
Indicator
HBT
LBRX
Relative Strength Index (RSI) 58.06 67.95
Support Level $35.34 $22.85
Resistance Level $37.17 $49.14
Average True Range (ATR) 0.73 2.51
MACD -0.25 -0.15
Stochastic Oscillator 41.90 85.38

Price Performance

Historical Comparison
HBT
LBRX

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: